Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 11, 2025 (Events reported April 11 and April 15, 2025)
Context: The Company, an emerging growth company incorporated in Texas, reported the entry into a material definitive agreement involving equity financing and the creation of a direct financial obligation via a promissory note.
Key Financial Metrics and Transactions
- Equity Financing: Sold 100 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $100,000 (April 11, 2025).
- Debt Financing: Borrowed $500,000 from Indigo Capital LP via a Promissory Note (April 15, 2025).
- Debt Terms: Interest rate of 18% per annum, compounded monthly. Maturity date is April 15, 2026, or earlier upon a Qualified Financing.
- Conversion Potential: The Series B Preferred Stock has a stated value of $1,100 per share. Full conversion of the April 11 issuance would result in approximately 73,333 shares of common stock at a conversion price of $1.50 per share.
- Liquidity and Margins: The filing does not provide specific revenue, profit, cash flow, or margin data.
Material Changes and Agreements
The filing details two primary material changes to the Company's capital structure:
- Securities Purchase Agreement (SPA):
- Includes a 18-month participation right for the Purchaser in subsequent financings up to the amount of their initial subscription ($100,000).
- Contains a 180-day restriction on entering into variable rate transactions.
- Promissory Note Obligations:
- Prepayment Penalty: Prepayment prior to maturity requires a premium equal to the interest that would have accrued until the stated maturity date.
- Default Consequences: Upon an event of default, the outstanding amount automatically increases to include a default amount equal to the remaining interest through the stated maturity date.
- Acceleration: The note is subject to mandatory prepayment within five business days following the closing of a Qualified Financing.
Guidance, Risks, and Contingencies
- Regulatory Status: The sale of Series B Preferred Stock was exempt from registration under Section 4(a)(2) and/or Rule 506 of Regulation D. Securities are subject to transfer restrictions.
- Financial Risks: The high interest rate (18%) and the "full interest" prepayment/default penalty structure create significant contingent liabilities that could impact future liquidity and dilution.
- Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding operational performance.
- Unusual Items: The prepayment terms are unusual as they require paying the full term's interest upon early repayment or default, rather than just accrued interest.
Investor Verification Checklist
- Verify the Company's current cash position to assess ability to service the 18% interest on the $500,000 note.
- Review the full text of the Promissory Note (Exhibit 10.2) to understand specific "Qualified Financing" definitions and default triggers.
- Confirm the total outstanding balance of Series B Preferred Stock and the aggregate potential dilution upon conversion.
- Check for any subsequent filings regarding the "Subsequent Financing" participation rights granted to the institutional investor.
- Assess the impact of the 180-day variable rate transaction restriction on future financing flexibility.